{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:46:48Z","timestamp":1791686808555,"version":"4.3.4"},"reference-count":18,"publisher":"SAABRON PRESS","issue":"3","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Managing multiple myeloma (MM) patients receiving advanced (four or more) lines of treatment is a complex challenge. Therefore, real-world data are essential to better understand and address the medical need of this challenging population. We used the EMMY cohort, a French longitudinal real-world study, to describe the characteristics and outcomes of 2127 MM patients receiving advanced-line treatments between 2017 and 2020. A wide variety of treatments were used without a predominant combination showing an evolution over time. Patients exhibited median time to next treatment and overall survival ranging from 7.8 months (95% CI: 6.7-7.8) and 19.4 months (95% CI: 17.4-22.5) in Line 4 (L4) to 4.8 months (95% CI: 3.5-6) and 12.6 months (95% CI: 8.7-16.6) in L8, respectively. The EMMY study provides valuable insights into the real-world application of advanced-line treatments, demonstrating rapid disease progression and poor outcomes in these patients before the novel anti-B-cell maturation antigen (BCMA) directed therapies. These findings highlight the critical need for novel therapies in this population.<\/jats:p>","DOI":"10.46989\/001c.143641","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T02:26:42Z","timestamp":1758162402000},"source":"Crossref","is-referenced-by-count":4,"title":["Improving Advanced-Line Multiple Myeloma Care: Insights and Real-World Challenges from the EMMY Study"],"prefix":"10.46989","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5834-5318","authenticated-orcid":true,"given":"Titouan","family":"Cazaubiel","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01hq89f96","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Hematology, H\u00f4pital Haut L\u00e9v\u00eaque, University Hospital, Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Decaux","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05qec5a53","id-type":"ROR","asserted-by":"publisher"}],"name":"Service d\u2019h\u00e9matologie clinique, UMR U1236, CHU de Rennes, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Royer","sequence":"additional","affiliation":[{"name":"Immuno-h\u00e9matologie, H\u00f4pital Saint Louis, APHP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Caillot","sequence":"additional","affiliation":[{"name":"H\u00e9matologie Clinique, CHU Dijon, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Bobin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/029s6hd13","id-type":"ROR","asserted-by":"publisher"}],"name":"H\u00e9matologie, CHU Poitiers, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Belhadj-Merzoug","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04m61mj84","id-type":"ROR","asserted-by":"publisher"}],"name":"Unit\u00e9 Fonctionnelle H\u00e9mopathies Lympho\u00efdes, Centre Hospitalier Universitaire Henri Mondor, Creteil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Macro","sequence":"additional","affiliation":[{"name":"Service d'h\u00e9matologie clinique, Centre Hospitalier Universitaire de Caen, Caen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Vincent","sequence":"additional","affiliation":[{"name":"CHU Montpellier - H\u00f4pital St Eloi, Service d'h\u00e9matologie clinique, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[{"name":"CHU Montpellier - H\u00f4pital St Eloi, Service d'h\u00e9matologie clinique, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse - Oncopole, Universit\u00e9 de Toulouse, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Karlin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/023xgd207","id-type":"ROR","asserted-by":"publisher"}],"name":"Service d\u2019H\u00e9matologie Clinique, H\u00f4pital Lyon Sud, Hospices Civils de Lyon, Pierre-B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Jacquet","sequence":"additional","affiliation":[{"name":"Service d\u2019h\u00e9matologie, CHU de Nancy - H\u00f4pitaux de Brabois, Vandoeuvre les Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Frenzel","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05tr67282","id-type":"ROR","asserted-by":"publisher"}],"name":"Service d'h\u00e9matologie adulte - Responsable centre r\u00e9gional de traitement de l'h\u00e9mophilie CRTH - Centre national de r\u00e9f\u00e9rence des mastocytoses CEREMAST, H\u00f4pital Necker-Enfant Malade, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Chalopin","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie et Th\u00e9rapie Cellulaire, CHU Tours, H\u00f4pital Bretonneau, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Sonntag","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04bckew43","id-type":"ROR","asserted-by":"publisher"}],"name":"D\u00e9partement d'H\u00e9matologie et Oncologie, H\u00f4pitaux Universitaires de Strasbourg, H\u00f4pital de Hautepierre et H\u00f4pital Civil, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Fontan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0084te143","id-type":"ROR","asserted-by":"publisher"}],"name":"Service H\u00e9matologie, CHRU Jean Minjoz, Besan\u00e7on, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Rigaudeau","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, CHV Andr\u00e9 Mignot, Universit\u00e9 Versailles Saint-Quentin, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05c1qsg97","id-type":"ROR","asserted-by":"publisher"}],"name":"Hematology Department, University Hospital H\u00f4tel-Dieu, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Demarquette","sequence":"additional","affiliation":[{"name":"Department of Hematology, CH, Dunkerque, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelaziz","family":"Chaib","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01txxxh71","id-type":"ROR","asserted-by":"publisher"}],"name":"Hemato-Oncologie et Medecine Interne, Centre Hospitalier du Pays d'Aix, Aix-en-Provence, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Santana","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02qykes20","id-type":"ROR","asserted-by":"publisher"}],"name":"Service H\u00e9matologie, Centre hospitalier de Valence, VALENCE, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Darre","sequence":"additional","affiliation":[{"name":"Department of Hematology, CH Arras, Arras, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Bareau","sequence":"additional","affiliation":[{"name":"Hematology, Les H\u00f4pitaux Priv\u00e9s Rennais Cesson S\u00e9vign\u00e9 - Vivalto Sant\u00e9, Cesson S\u00e9vign\u00e9, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Garlant\u00e9zec","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05qec5a53","id-type":"ROR","asserted-by":"publisher"}],"name":"Sant\u00e9 publique et \u00e9pid\u00e9miologie, CHU de Rennes, Rennes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Hulin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01hq89f96","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Hematology, H\u00f4pital Haut L\u00e9v\u00eaque, University Hospital, Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"issue":"12","key":"ref1","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1038\/s41375-024-02404-6","article-title":"LocoMMotion: A study of real-life current standards of care in triple-class exposed patients with relapsed\/refractory multiple myeloma \u2013 2-year follow-up (final analysis)","volume":"38","author":"M.-V. Mateos","year":"2024","journal-title":"Leukemia"},{"issue":"8","key":"ref2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral Selinexor\u2013Dexamethasone for Triple-Class Refractory Multiple Myeloma","volume":"381","author":"A. Chari","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"ref3","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1007\/s00277-021-04522-y","article-title":"Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France\u2014A cohort study using the French National Healthcare database (SNDS)","volume":"100","author":"C. Touzeau","year":"2021","journal-title":"Annals of Hematology"},{"issue":"9","key":"ref4","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of Patients with Multiple Myeloma Refractory to CD38-Targeted Monoclonal Antibody Therapy","volume":"33","author":"U. H. Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"10","key":"ref5","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1016\/j.clml.2018.06.018","article-title":"Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study","volume":"18","author":"M. Mohty","year":"2018","journal-title":"Clinical Lymphoma, Myeloma and Leukemia"},{"issue":"1","key":"ref6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/ejh.13976","article-title":"Survival outcomes for patients with multiple myeloma in France: A retrospective cohort study using the Syst\u00e8me National des Donn\u00e9es de Sant\u00e9 national healthcare database","volume":"111","author":"X. Leleu","year":"2023","journal-title":"European Journal of Haematology"},{"issue":"2","key":"ref7","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: Patient outcomes in real-world practice","volume":"175","author":"K. Yong","year":"2016","journal-title":"British Journal of Haematology"},{"issue":"1","key":"ref8","doi-asserted-by":"publisher","first-page":"4625787","DOI":"10.1155\/2019\/4625787","article-title":"Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France","volume":"2019","author":"H. M. Lin","year":"2019","journal-title":"Advances in Hematology"},{"issue":"11","key":"ref9","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1038\/leu.2017.138","article-title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study","volume":"31","author":"S. K. Kumar","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"ref10","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: Recommendations from the International Myeloma Working Group","volume":"22","author":"P. Moreau","year":"2021","journal-title":"The Lancet Oncology"},{"issue":"8","key":"ref11","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"N. C. Munshi","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"10297","key":"ref12","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"J. G. Berdeja","year":"2021","journal-title":"The Lancet"},{"issue":"6","key":"ref13","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"P. Moreau","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"ref14","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results","volume":"29","author":"A. M. Lesokhin","year":"2023","journal-title":"Nature Medicine"},{"issue":"9","key":"ref15","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.clml.2017.06.013","article-title":"Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes","volume":"17","author":"J. J. Shah","year":"2017","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"issue":"3","key":"ref16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.46989\/001c.121371","article-title":"The EMMY longitudinal, cohort study: Real-world data to describe multiple myeloma management and outcomes as more therapeutic options emerge","volume":"6","author":"O. Decaux","year":"2024","journal-title":"Clinical Hematology International"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.09.006","article-title":"Real-Life Management of Patients Aged 80 Years Old and Over With Multiple Myeloma: Results of the EMMY Cohort","author":"T. Chalopin","year":"2024","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"issue":"11","key":"ref18","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1634\/theoncologist.2016-0104","article-title":"Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With \u22653 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD","volume":"21","author":"S. Usmani","year":"2016","journal-title":"The Oncologist"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/chi.scholasticahq.com\/article\/143641-improving-advanced-line-multiple-myeloma-care-insights-and-real-world-challenges-from-the-emmy-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T01:47:56Z","timestamp":1791683276000},"score":1,"resource":{"primary":{"URL":"https:\/\/chi.scholasticahq.com\/article\/143641-improving-advanced-line-multiple-myeloma-care-insights-and-real-world-challenges-from-the-emmy-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":18,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.46989\/001c.143641","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]}}}